"As expected, there is also a good correlation between CytoSorb™ cytokine reduction and outcome in patients with highly elevated IL-6 levels (greater than or equal to 1,000 pg/mL) or IL-1ra (greater than or equal to 16,000 pg/mL) which are both known, independent predictors of mortality in sepsis. In these patients, CytoSorb™ treatment showed positive trends to benefit in 28-day all-cause mortality (0% vs 62.5% control, n = 14), fewer patients on mechanical ventilation at 28 days (33% vs 88% control), and fewer days in the ICU (23.8 vs 27.5 days control). "
I'd like to focus on just that last statistic: "...fewer days in the ICU (23.8 vs 27.5 days control)."....FOUR FEW DAYS IN ICU than the control group.
At enormous costs for a fully staffed ICU with all the related drips, monitors, etc.etc.etc. we are talking maybe $25,000 to $70,000--per day--according to my research...That's a $100,000 to $280,000 cost savings to hospitals and insurers..All for less than $10,000 in Cytosorbent filters, maybe a bit more but not much.
Now, according to the PR quote above, CTSO is already getting these numbers (23.8 vs 27.5 days control)....Further testing by additional and influential KOL's are likely to ADD "icing-to-the-cake" so to speak....I believe it's highly unlikely that these newer KOL's Dr. Chan wants to include in the dosing study will go against or disagree with these numbers stated above (23.8 vs 27.5 days control)....THIS IS THE MEAT OF THE ARGUEMENT FOR HOLDING ONTO YOUR/MY SHARES.
All the rest is investor "noise", "confusion", and baseless speculation.....Folks WE'VE BEEN GIVEN THE KEY NUMBERS ALREADY....The delay to add key KOL's professional input into the dosing study that the company WILL BE releasing, is just ICING ON THE CAKE.
Hi Warren, I like your post and enthusiasm. Your numbers are a bit off. ;-) According to CytoSorbents, cost to treat a sepsis patient is approx $3,000 per day in the ICU. A burn patient with more than 30% of his total body surface area burned can cost as much as $200,000 to treat.
One CytoSorb cartridge cost over $500. From the last OneMed presentation, Dr Chan states that a the full course of treatment (7 days currently), is ~$3,500 – $5,000. Dr Chan anticipates that the trial sites will be customers in the future. We can expect revenue from 7 hospitals later!
Below is CytoSorbents' research on cost of treating sepsis patient:
"In addition to the human toll, sepsis is one of the most expensive acute care diseases to treat. Severe sepsis
patients account for up to 20% of all intensive care unit (ICU) admissions and require expensive and highly variable treatment and
diagnostic procedures. For example, a septic patient in the ICU typically has multi-organ dysfunction requiring constant skilled
nursing care and the use of expensive, supportive therapies such as mechanical ventilation, dialysis, and the administration of blood
products, vasopressors, and costly drugs and antibiotics. These patients also undergo a wide range of other procedures including
diagnostic imaging (X-rays, CT, MRI, ultrasound), blood tests, arterial blood gases, placement of blood and urine catheters,
amongst others. In many cases, patients require some kind of surgical exploration, resection and debridement of necrotic tissues or
fluid. The treatment of most sepsis patients in the ICU is also multi-disciplinary, often requiring the expertise of consultants in
infectious disease, nephrology, surgery, nutrition and other fields. It is therefore not surprising that in 2001, the average cost per
day in the ICU, the overall hospital cost and the total hospital length of stay of a sepsis patient requiring ICU care was nearly $3,000
a day, $39,949 ± 45,278 and 19 ± 19.4 days, respectively.2 Another 2001 study concluded similar costs and estimated the total
annual U.S. burden of sepsis at $16.7 billion, leading to substantial losses for the healthcare system.3 These expenses have
significantly increased over the past decade due to rising healthcare costs, an increase in sepsis incidence, and a continued lack of
effective “active” therapies to reverse the underlying cause of sepsis and organ failure."